Dietary and pharmacological antioxidants in atherosclerosis.
Antioxidants that inhibit LDL oxidation are thought to be potential anti-atherogenic compounds. The results of major human randomized trials with antioxidants have, however, been disappointing, except for probucol, which consistently inhibits restenosis. Similarly, animal intervention studies show that antioxidants do not generally inhibit atherosclerosis, although some compounds provide protection. Direct evidence for the oxidation of LDL causing atherosclerosis is needed. This article summarizes results from antioxidant intervention studies, and highlights some of the key issues that need to be addressed to link biochemical changes in the arterial wall more directly to the oxidation theory of atherosclerosis.
Stocker
R
R
Biochemistry Group, Heart Research Institute, Camperdown, NSW, Australia. r.stocker@hri.org.au
D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000097:blood / Q000517:prevention & control*; D003327:Coronary Disease / Q000097:blood / Q000503:physiopathology; D004032:Diet; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood
D000975:Antioxidants; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein